Read the latest press releases from Calliditas Therapeutics by clicking on a title below.

For press enquiries please contact us.

Calliditas appoints new Chief Medical Officer

Calliditas moves its Annual General Meeting 2020 to June 25

Bulletin from the extraordinary general meeting of Calliditas Therapeutics AB (publ)

Year-End Report 2019

Notice of extraordinary general meeting of Calliditas Therapeutics AB (publ)

Calliditas submits draft registration statement for the listing of ADSs in the U.S.

Completion of recruitment of Part A of the NeflgArd pivotal Phase 3 clinical trial by year end

China IND approval triggers $5 million milestone payment from Everest Medicines

Krassimir Mitchev steps up as acting CMO

Interim Report Q3, 2019

Calliditas Therapeutics’ nomination committee for the AGM 2020

Positive interactions with EMA provide route to conditional marketing authorization of lead candidate Nefecon

Positive feedback from FDA significantly benefits ongoing NefIgArd pivotal Phase 3 study

Interim Report Q2, 2019

Strategic in-licensing related to autoimmune hepatitis in the US market

Number of shares and votes in Calliditas Therapeutics

Calliditas has resolved on a directed share issue in the amount of 3.5 million shares, raising proceeds of approximately SEK 210 million

Calliditas considers a directed share issue

Calliditas Therapeutics and Everest Medicines Enter into an Agreement to Develop and Commercialize Nefecon for IgA Nephropathy in Greater China and Singapore

Bulletin from the annual general meeting of Calliditas Therapeutics AB (publ)

Interim Report Q1, 2019

Notice of annual general meeting of Calliditas Therapeutics AB (publ)

Calliditas Therapeutics’ 2018 Annual Report published

Calliditas Therapeutics granted orphan drug designation by the FDA for Primary biliary cholangitis

Year-end report, 2018

Calliditas Therapeutics granted orphan drug designation by the FDA for Autoimmune hepatitis

Bulletin from extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)

Notice of extraordinary shareholders’ meeting of Calliditas Therapeutics AB (publ)

First patient enrolled in pivotal clinical phase 3 study NEFIGARD with lead candidate Nefecon

Interim Report Q3, 2018

Calliditas Therapeutics’ nomination committee for the AGM 2019

Interim Report Q2, 2018

Number of shares and votes in Calliditas Therapeutics

Exercise of over-allotment option and end of the stabilization period

Stabilization notice

Number of shares and votes in Calliditas Therapeutics

Calliditas announces listing on Nasdaq Stockholm and related prospectus